Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ NDA submitted for presbyopia treatment ➤ FDA approves AMD treatment ➤ Primary endpoint achieved in Phase 3 trial of reproxalap for dry eye ➤ Clinical trial results that supported new excimer laser approval published ➤ Company updates on several clinical trials ➤ First patient dosed in Phase 2 trial for intravitreal steroid implant for DME treatment ➤ ASCRS news and events
While there a lot of different technologies that can give patients excellent refractive results after cataract surgery, this area keeps expanding and improving. As more options become available, it increases the complexity of talking to patients. This is what the symposium Having “The Talk” focused on at the 2024 ASCRS Annual Meeting.
➤ Phase 3 results for new corticosteroid ➤ Positive topline results from Phase 3 trials investigating presbyopia drop ➤ Phase 2 data presented for IOP-lowering intracameral implant ➤ First patient dosed in retinitis pigmentosa gene therapy ➤ Survey shows burden of pterygium ➤ ASCRS news and events
➤ FDA approves updated femtosecond laser for refractive surgery ➤ Positive topline results from Phase 3, first-in-class dry eye disease studies ➤ Rare Disease Designation granted for investigational gene therapy ➤ Positive interim data for investigational Stargardt disease treatment ➤ First patient dosed in Phase 2 trial for DME treatment ➤ Research program established to investigate whole eye transplant ➤ ASCRS news and events
John Marshall, MD, PhD, discusses work being done on laser scleral microporation, a technique that he thinks could “rejuvenate” the eye’s natural dynamically focusing process.
➤ FDA approves presbyopia drop ➤ FDA approves expanded capabilities on anterior segment diagnostic platform ➤ Phase 4 data presented for dry eye disease drug ➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy ➤ Reports suggest reproxalap NDA might not be approved ➤ Companies partner to develop gene therapy ➤ ASCRS news and events
Several physicians discussed their experience using Vuity (Allergan) in practice and how it has, or has not, worked for their patients. They also gave their thoughts on the future of the presbyopia drop market and other products in the pipeline.
➤ Topline data from Phase 3 presbyopia drop trial ➤ Femtosecond laser for LASIK receives FDA clearance ➤ Enrollment complete for hydrophobic trifocal IOL trial ➤ Early results from clinical trial for dry eye therapy ➤ FDA clears IND application for clinical trial of therapy for X-linked retinoschisis ➤ Innovations in capsulotomy creation device ➤ Company acquisition news ➤ ASCRS news and events
➤ FDA approves new monofocal IOL ➤ Topline Phase 3 results for fixed-dose combination presbyopia drop ➤ Gene therapy trial produces positive Phase 1/2 data for Leber congenital amaurosis ➤ New data shows investigational compound protects endothelium for cataract patients undergoing Fuchs treatment ➤ ASCRS news and events
The Casey Eye Institute ophthalmology residents review this article from the December 2022 issue of the Journal of Cataract & Refractive Surgery.